Cost of immunization with a locally produced, oral cholera vaccine in Viet Nam

被引:15
作者
Naficy, AB
Trach, DD
Ke, NT
Chuc, NTK
Sorkin, A
Rao, MR
Sy, TH
Thiem, VD
Canh, DG
Mahoney, RT
Holmgren, J
Ivanoff, B
Clemens, JD
机构
[1] NICHHD, Epidemiol Branch, Rockville, MD 20852 USA
[2] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam
[3] Natl Inst Vaccines & Biol Subst, Nha Trang, Vietnam
[4] Ctr Social Sci Hlth, Hanoi, Vietnam
[5] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA
[6] Univ Maryland Baltimore Cty, Catonsville, MD USA
[7] Khanh Hoa Hlth Serv, Nha Trang, Vietnam
[8] Int Vaccine Inst, Seoul, South Korea
[9] Univ Gothenburg, Gothenburg, Sweden
[10] WHO, CH-1211 Geneva, Switzerland
关键词
cholera; immunization; cost;
D O I
10.1016/S0264-410X(01)00089-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Policy decisions regarding whether to incorporate new vaccines into routine public health practice in developing countries will depend in part on the costs of vaccine purchase and of vaccine delivery. In March, 1997, a large-scale effectiveness trial of a locally produced, orally administered bivalent vaccine against Vibrio cholerae 01 and 0139 began in Viet Nam. Empirical data obtained from the trial was used to determine the costs of the immunization campaign from the government perspective. The study population, including the children less than one year of age and pregnant women who were ineligible for immunization, was 353926. A total of 289041 persons received two doses of vaccine, and 13340 persons received one dose of vaccine. Two-dose vaccine coverage was 83.4%. The total cost of vaccine delivery during the immunization campaign was $66527. The cost of each dose of vaccine was $0.31. Therefore. the total cost of the immunization campaign was $0.44 per dose administered, and $0.91 per fully immunized person. Attempts to reduce the cost per dose of vaccine (e.g. the use of a monovalent vaccine against serogroup 01) are likely to have a large impact on the cost of future similar immunization campaigns. Published by Elevier Science Ltd.
引用
收藏
页码:3720 / 3725
页数:6
相关论文
共 17 条
[11]  
CUTTING WAM, 1980, LANCET, V2, P634
[12]  
*EP, 1998, US 2 DOS OR CHOL VAC
[13]   Prospects for the use of new vaccines in developing countries: Cost is not the only impediment [J].
Hausdorff, WP .
VACCINE, 1996, 14 (13) :1179-1186
[14]   Future vaccines and a global perspective [J].
Katz, SL .
LANCET, 1997, 350 (9093) :1767-1770
[15]   Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study [J].
Murray, CJL ;
Lopez, AD .
LANCET, 1997, 349 (9063) :1436-1442
[16]   Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings - A cost-effectiveness analysis [J].
Naficy, A ;
Rao, MR ;
Paquet, C ;
Antona, D ;
Sorkin, A ;
Clemens, JD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (07) :521-525
[17]   PROTECTIVE EFFICACY OF ORAL WHOLE-CELL RECOMBINANT-B-SUBUNIT CHOLERA VACCINE IN PERUVIAN MILITARY RECRUITS [J].
SANCHEZ, JL ;
VASQUEZ, B ;
BEGUE, RE ;
MEZA, R ;
CASTELLARES, G ;
CABEZAS, C ;
WATTS, DM ;
SVENNERHOLM, AM ;
SADOFF, JC ;
TAYLOR, DN .
LANCET, 1994, 344 (8932) :1273-1276